Clinical Edge Journal Scan

Fluctuating and persistent depressive symptoms in patients with atopic dermatitis


 

Key clinical point: Patients with atopic dermatitis (AD) experience a fluctuation in depression severity over time, with the likelihood of experiencing depressive symptoms being the highest in patients with severe AD.

Major finding: Among patients with ≥2 follow-up visits, most (49.46%) experienced a fluctuation in depression severity, whereas 45.65% experienced a persistent severity of depression. High Eczema Area Severity Index (adjusted odds ratio [aOR] 7.622; 95% CI 3.881-14.968) and itch (aOR 14.745; 95% CI 4.696-46.297) scores were strongly associated with difficulty in concentrating over time.

Study details: Findings are from a longitudinal, dermatology practice-based study including 695 adults with AD who were evaluated at baseline and at every 6-month follow-up visits.

Disclosures: This study was funded by the US Agency for Healthcare Research and Quality, the Dermatology Foundation, and Galderma. R Chavda and S Gabriel declared being employees of Galderma, and JI Silverberg declared serving as a consultant for Galderma.

Source: Chatrath S et al. Longitudinal course and predictors of depressive symptoms in atopic dermatitis. J Am Acad Dermatol. 2022 (May 9). Doi: 10.1016/j.jaad.2022.04.061

Recommended Reading

Dupilumab beneficial for adolescents with moderate-to-severe atopic dermatitis in the real world
MDedge Dermatology
Meta-analysis highlights favorable efficacy and safety of antioxidants in atopic dermatitis
MDedge Dermatology
Children with atopic dermatitis prone to develop proinflammatory dietary pattern
MDedge Dermatology
Detrimental impact of atopic dermatitis on families of pediatric patients
MDedge Dermatology
Commentary: Comparisons of Dupilumab and Other Atopic Dermatitis Treatments, June 2022
MDedge Dermatology
FDA approves dupilumab for children with eczema aged 6 months to 5 years
MDedge Dermatology
Therapeutic patient education can help with adherence to treatment
MDedge Dermatology
Atopic dermatitis: Options abound, and more are coming
MDedge Dermatology
Long-term safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis
MDedge Dermatology
Moderate-to-severe atopic dermatitis: Rapid improvement in itch with baricitinib vs. dupilumab
MDedge Dermatology